ArticleOxford medical case reports2026
A case of anti-nephrin antibody-positive, steroid-dependent nephrotic syndrome with successful discontinuation of immunosuppressants following rituximab.
Article in Oxford medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Minimal change nephrotic syndrome (MCNS) is a major cause of nephrotic syndrome in children and adults. Recent studies identified circulating anti-nephrin antibodies in 30%-50% of patients, linking them to severe proteinuria and frequent relapses. We describe a Japanese woman in her 40s with steroid-dependent nephrotic syndrome (SDNS). Anti-nephrin antibodies were identified in serum obtained at disease onset by immunoprecipitation and ELISA, and kidney biopsy showed punctate IgG colocalizing with nephrin. Before rituximab (RTX), she experienced relapses accompanied by increased anti-nephrin antibody reactivity. A low-dose RTX regimen (200 mg every 6 months for seven doses) enabled maintenance of complete remission and discontinuation of prednisolone and cyclosporine, with B-cell depletion confirmed by CD19 monitoring. She has maintained remission for two years after RTX discontinuation, without re-elevation of anti-nephrin antibody reactivity. This case supports a possible role of anti-nephrin antibodies in disease activity and suggests that low-dose RTX may contribute to durable remission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.